An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

March 8, 2022

Primary Completion Date

April 1, 2032

Study Completion Date

April 2, 2034

Conditions
Methylmalonic Acidemia
Interventions
DRUG

mRNA-3705

A sterile liquid for injection

Trial Locations (12)

28041

RECRUITING

Hospital Universitario 12 de Octubre, Madrid

48903

RECRUITING

Hospital Universitario Cruces, Barakaldo

75015

RECRUITING

Hôpital Necker - Enfants Malades APHP, Paris

90095

RECRUITING

UCLA Medical Center, Los Angeles

92037

RECRUITING

Altman Clinical and Translational Research Institution, San Diego

94304

RECRUITING

Lucile Packard Children's Hospital at Stanford, Palo Alto

T6G 2R7

RECRUITING

Stollery Children's Hospital University of Alberta, Edmonton

M5G 1X8

RECRUITING

Hospital For Sick Children, Toronto

3015 AA

RECRUITING

Erasmus MC, Rotterdam

3584 CX

RECRUITING

Universitair Medisch Centrum Utrecht, Utrecht

B4 6NH

TERMINATED

Birmingham Children's Hospital NHS Foundation Trust, Birmingham

M13 9WL

RECRUITING

Royal Manchester Childrens Hospital, Manchester

All Listed Sponsors
lead

ModernaTX, Inc.

INDUSTRY